New York, NEW%20YORK79 Active Studies

Pulmonary Hypertension Clinical Trials in New York, NEW%20YORK

Find 79 actively recruiting pulmonary hypertension clinical trials in New York, NEW%20YORK. Connect with local research sites and explore new treatment options.

79
Active Trials
53
Sponsors
12,158
Enrolling

Recruiting Pulmonary Hypertension Studies in New York

RecruitingNew York, NEW%20YORKNCT04685616

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) an...

1,042 participants
University College, London
View Study Details
RecruitingNew York, NEW%20YORKNCT03075696

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

This is a Phase I/II, multicenter, open-label, dose-escalation study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, a...

920 participants
Hoffmann-La Roche
View Study Details
RecruitingNew York, NEW%20YORKNCT05283720

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability o...

565 participants
Genmab
View Study Details
RecruitingNew York, NEW%20YORKNCT06091254

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin...

478 participants
Regeneron Pharmaceuticals
View Study Details
RecruitingNew York, NEW%20YORKNCT07029217

A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas

The researchers are doing this study to find out whether a very low dose of radiation therapy (VLDRT) is an effective treatment for people with follicular lymphoma (FL) or marginal zone lymphoma (MZL)...

375 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT03817502

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population....

330 participants
Gedeon Richter Plc.
View Study Details
RecruitingNew York, NEW%20YORKNCT04924075

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Li...

322 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNew York, NEW%20YORKNCT06090539

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrad...

308 participants
Bristol-Myers Squibb
View Study Details
RecruitingNew York, NEW%20YORKNCT05005975

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

To evaluate the long-term safety and tolerability of oral dersimelagon....

301 participants
Mitsubishi Tanabe Pharma America Inc.
View Study Details
RecruitingNew York, NEW%20YORKNCT04521231

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

The Phase I part of the study aims to evaluate the safety, efficacy, and tolerability of subcutaneous (SC) blinatumomab for treatment of Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leu...

281 participants
Amgen
View Study Details
RecruitingNew York, NEW%20YORKNCT05208190

Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial

Two-hundred and eighty individuals with schizophrenia who have a recent history of violent acts will be randomized in this 2-arm, parallel-group, 24-week, open-label, 7-site clinical trial to examine ...

280 participants
New York State Psychiatric Institute
View Study Details
RecruitingNew York, NEW%20YORKNCT06876662

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-...

279 participants
Eli Lilly and Company
View Study Details
RecruitingNew York, NEW%20YORKNCT06564038

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

The purpose of this study is to assess the safety and efficacy of AZD0486 administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies....

276 participants
AstraZeneca
View Study Details
RecruitingNew York, NEW%20YORKNCT04104776

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid ...

275 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNew York, NEW%20YORKNCT05568719

Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatm...

263 participants
Pfizer
View Study Details
RecruitingNew York, NEW%20YORKNCT03618550

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma....

257 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT06526793

AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of AZD0486 monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lympho...

240 participants
AstraZeneca
View Study Details
RecruitingNew York, NEW%20YORKNCT05082519

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients w...

240 participants
Etan Orgel
View Study Details
RecruitingNew York, NEW%20YORKNCT03824483

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and ven...

230 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT05319730

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

This is a Phase 1/2, multicenter, randomized, open-label umbrella platform study to evaluate the safety and efficacy of investigational agents with or without pembrolizumab and/or chemotherapy, for th...

230 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNew York, NEW%20YORKNCT06643481

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of...

225 participants
Novartis Pharmaceuticals
View Study Details
RecruitingNew York, NEW%20YORKNCT05166161

A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein cons...

200 participants
PTC Therapeutics
View Study Details
RecruitingNew York, NEW%20YORKNCT06088654

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

This is an international, first-in-human, multicenter, open-label Phase 1/2 study to evaluate the safety profile, tolerability of IPH6501, and determine the recommended phase 2 dose (RP2D) for patient...

184 participants
Innate Pharma
View Study Details
RecruitingNew York, NEW%20YORKNCT05463263

A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas....

180 participants
Step Pharma, SAS
View Study Details
RecruitingNew York, NEW%20YORKNCT06542250

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Ma...

174 participants
AstraZeneca
View Study Details
RecruitingNew York, NEW%20YORKNCT05263934

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

This study aims to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA receiving SoC therapy....

160 participants
GlaxoSmithKline
View Study Details
RecruitingNew York, NEW%20YORKNCT05416307

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of th...

156 participants
Electra Therapeutics Inc.
View Study Details
RecruitingNew York, NEW%20YORKNCT06910358

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

The goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin incre...

150 participants
Disc Medicine, Inc
View Study Details
RecruitingNew York, NEW%20YORKNCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in par...

142 participants
AstraZeneca
View Study Details
RecruitingNew York, NEW%20YORKNCT06814145

Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)

Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH). This study focuses on Cpc-PH ...

130 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNew York, NEW%20YORKNCT06469944

Substudy 06C: A Study of Sacituzumab Tirumotecan (MK-2870) With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of sacituzumab tirumotecan with pembrolizumab and fluoropyrimidine chemotherapy for ...

130 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNew York, NEW%20YORKNCT06238648

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

This phase II trial compares epcoritamab to standard practice (observation) for the treatment of patients with B-cell lymphomas who are not in complete remission after treatment with CD19-directed chi...

120 participants
Academic and Community Cancer Research United
View Study Details
RecruitingNew York, NEW%20YORKNCT06496750

Ketamine for Methamphetamine Use Disorder

This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD. The study design is a 12-week rando...

120 participants
University of Texas Southwestern Medical Center
View Study Details
RecruitingNew York, NEW%20YORKNCT05721222

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers. Part...

110 participants
Genmab
View Study Details
RecruitingNew York, NEW%20YORKNCT02315326

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvicaâ„¢). At this stage of this trial, the study is investigating whether Ibrutinib...

109 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT05538208

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every ...

105 participants
Children's Hospital Medical Center, Cincinnati
View Study Details
RecruitingNew York, NEW%20YORKNCT06457503

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

This study aims to investigate toripalimab with chemotherapy in participants with nasopharyngeal cancer....

100 participants
Coherus Oncology, Inc.
View Study Details
RecruitingNew York, NEW%20YORKNCT04039464

Mono vs. Dual Therapy for Pediatric Pulmonary Arterial Hypertension

The investigators' central hypothesis is that early combination therapy with two PAH-specific oral therapies that have been shown to be well tolerated in the pediatric population, sildenafil and bosen...

100 participants
Johns Hopkins University
View Study Details
RecruitingNew York, NEW%20YORKNCT05848687

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets...

90 participants
Tanja Andrea Gruber
View Study Details
RecruitingNew York, NEW%20YORKNCT06445972

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of sacituzumab tirumotecan (MK-2870) plus paclitaxel versus ramucirumab plus paclitaxel, ...

90 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingNew York, NEW%20YORKNCT05419089

The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)

The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with t...

83 participants
Icahn School of Medicine at Mount Sinai
View Study Details
RecruitingNew York, NEW%20YORKNCT02974647

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT...

82 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT06502964

Study of ALTO-101 in Patients With Schizophrenia

This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers an...

82 participants
Alto Neuroscience
View Study Details
RecruitingNew York, NEW%20YORKNCT04419519

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop tr...

80 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT06634589

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed...

80 participants
BeiGene
View Study Details
RecruitingNew York, NEW%20YORKNCT06470451

Confirmatory Study of Topical HyBryteâ„¢ vs. Placebo for the Treatment of CTCL

To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides)....

80 participants
Soligenix
View Study Details
RecruitingNew York, NEW%20YORKNCT05389293

A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma

The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their di...

76 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT06347159

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

This study is being conducted in order to understand the safety and effects of different doses of EDG-7500 as a single dose in adults with obstructive hypertrophic cardiomyopathy (oHCM) and as multipl...

75 participants
Edgewise Therapeutics, Inc.
View Study Details
RecruitingNew York, NEW%20YORKNCT06848231

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multip...

75 participants
Yoda Therapeutics Inc.
View Study Details
RecruitingNew York, NEW%20YORKNCT06377566

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

The purpose of this study is to test whether BV-AVD is an effective treatment in people with early stage, bulky Hodgkin lymphoma that was recently diagnosed and who have not yet received any treatment...

71 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT05475925

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

This is a multicenter, first-in-human, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular ...

69 participants
Dren Bio
View Study Details
RecruitingNew York, NEW%20YORKNCT05533775

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and et...

65 participants
Hoffmann-La Roche
View Study Details
RecruitingNew York, NEW%20YORKNCT03152058

IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid...

55 participants
David Ware Branch
View Study Details
RecruitingNew York, NEW%20YORKNCT04150497

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

52 participants
Cellectis S.A.
View Study Details
RecruitingNew York, NEW%20YORKNCT06450639

A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)

The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in a...

50 participants
Hoffmann-La Roche
View Study Details
RecruitingNew York, NEW%20YORKNCT04747236

Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL

The purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will ...

50 participants
University of Virginia
View Study Details
RecruitingNew York, NEW%20YORKNCT06736613

A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma

The purpose of this study is to find out how many people with B-cell lymphoma who are at high risk for central nervous system/CNS relapse test positive for cerebral spinal fluid/CSF ctDNA but test neg...

50 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT06123338

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer....

49 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT06534060

MB-105 in Patients With CD5 Positive T-cell Lymphoma

This is a single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL). This study will apply a Simon tw...

46 participants
March Biosciences Inc
View Study Details
RecruitingNew York, NEW%20YORKNCT04626791

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

This phase II trial investigates how well modified VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, and cytarabine hydrochloride) and acalabrutinib as first line...

45 participants
Academic and Community Cancer Research United
View Study Details
RecruitingNew York, NEW%20YORKNCT06563596

Epco, Zanu, Ritux for R/R FL or MZL

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma ...

45 participants
Reid Merryman, MD
View Study Details
RecruitingNew York, NEW%20YORKNCT03104491

Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia

This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects ...

44 participants
Leland Metheny
View Study Details
RecruitingNew York, NEW%20YORKNCT06765317

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

The researchers are doing this study to find out if the study treatment is an effective treatment that causes few or mild side effects in people with diffuse large B-cell lymphoma (DLBCL), high-grade ...

42 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT06849713

Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small...

40 participants
Massachusetts General Hospital
View Study Details
RecruitingNew York, NEW%20YORKNCT06239480

SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations

SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations The main purp...

40 participants
Palvella Therapeutics, Inc.
View Study Details
RecruitingNew York, NEW%20YORKNCT04421560

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: ...

37 participants
Dana-Farber Cancer Institute
View Study Details
RecruitingNew York, NEW%20YORKNCT05934448

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

This research study is evaluating the combination of drugs, pembrolizumab with chimeric antigen receptor (CAR) T-cell therapy, as a possible treatment for primary mediastinal B-cell lymphoma that has ...

35 participants
Jennifer Crombie, MD
View Study Details
RecruitingNew York, NEW%20YORKNCT06844214

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 50 Years of Age With Non-congenital Myotonic Dystrophy Type 1

This is a Phase 1/Phase 2 open-label single arm, multicenter, and multinational study with SAR446268 for treatment of male and female participants 10 to 50 years old with non-congenital myotonic dystr...

32 participants
Sanofi
View Study Details
RecruitingNew York, NEW%20YORKNCT05307939

A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)

This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC. All participants will have recently had surgery to treat their dis...

30 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT06954805

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

The purpose of this study is to find out if there is a benefit to giving rituximab with etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (R-EPOCH) in participants who have high-ris...

30 participants
Jennifer Amengual
View Study Details
RecruitingNew York, NEW%20YORKNCT05861986

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy

This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered as an early intervention in pediatric participants with spinal muscular...

28 participants
Hoffmann-La Roche
View Study Details
RecruitingNew York, NEW%20YORKNCT06175000

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer ...

28 participants
Providence Health & Services
View Study Details
RecruitingNew York, NEW%20YORKNCT05592015

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the...

28 participants
Jonathan Brammer
View Study Details
RecruitingNew York, NEW%20YORKNCT07030699

A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma

The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL. This is th...

27 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT04872543

A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)

The purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs (cedazuridine and de...

25 participants
Memorial Sloan Kettering Cancer Center
View Study Details
RecruitingNew York, NEW%20YORKNCT05480384

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

An open label phase II study to determine the safety and preliminary efficacy of the combination of 1-year of adjuvant trastuzumab deruxtecan and nivolumab for patients with HER2 overexpressing esopha...

25 participants
Brown University
View Study Details
RecruitingNew York, NEW%20YORKNCT05671757

Daratumumab in Primary Antiphospholipid Syndrome

The purpose of this study is to see if the study medication, daratumumab, is safe to treat individuals with Anti-Phospholipid Syndrome (APS). Three daratumumab dosing cohorts are planned with up to s...

22 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingNew York, NEW%20YORKNCT06983158

A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy

The goal of this clinical trial is to learn about the safety of CAP-002 gene therapy in children with Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy. It will also provide information about whether...

12 participants
Capsida Biotherapeutics, Inc.
View Study Details
RecruitingNew York, NEW%20YORKNCT06662188

JAG201 Gene Therapy Study in Children & Adults With SHANK3 Haploinsufficiency

This is a Phase 1/2, first in human, open-label, dose-escalation study to evaluate the safety, tolerability, and clinical activity of a single dose of JAG201 administered via intracerebroventricular (...

6 participants
Jaguar Gene Therapy, LLC
View Study Details

About Pulmonary Hypertension Clinical Trials in New York

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 79 pulmonary hypertension clinical trials recruiting participants in New York, NEW%20YORK. These studies are seeking a combined 12,158 participants. Research is being sponsored by University College, London, Hoffmann-La Roche, Genmab and 50 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in New York — FAQ

Are there pulmonary hypertension clinical trials in New York?

Yes, there are 79 pulmonary hypertension clinical trials currently recruiting in New York, NEW%20YORK. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New York?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New York research site will contact you about next steps.

Are clinical trials in New York free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New York studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 79 active trials in New York are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated March 2, 2026 from ClinicalTrials.gov